The objective of secondary prevention in adrenoleukodystrophy is to diagnose it early, preferably before neurological symptoms appear so as to prevent nerve cell damage from occurring, initiating timely adrenal steroid replacement therapy following detection of adrenal insufficiency, and for providing allogeneic hematopoietic stem cell transplantation (HSCT) as a means of treating cerebral ALD. In February 2016, adrenoleukodystrophy was added to the Recommended Uniform Screening Panel (RUSP) in the USA, which is the federal list of all genetic diseases recommended for state newborn screening programs.
Adrenoleukodystrophy secondary prevention
Multiple sclerosis alternative therapies
Multiple sclerosis primary prevention
Multiple sclerosis tertiary prevention
Parkinson's disease primary prevention
Adrenoleukodystrophy future or investigational therapies
Polymyositis and dermatomyositis secondary prevention
Tropical spastic paraparesis primary prevention